Research Corner: Health Disparities Focus Group
By Dorothy Reed, Chair, Community Cancer Action Board
Palliative Medicine and Supportive Care Program
.divTable{
display: table;
width: 100%;
}
.divTableRow {
display: table-row;
}
.divTableHeading {
background-color: #EEE;
display: table-header-group;
}
.divTableCell, .divTableHead {
display: table-cell;
padding: 3px 10px;
height: auto;
width: 50%;
}
.divTableBody {
display: table-row-group;
}
CAR T-Cell Therapy Available at Rutgers Cancer Institute and Robert Wood Johnson University Hospital
Between 60 to 70 percent of patients with aggressive non-Hodgkin lymphoma are cured with initial chemotherapy and a significant percentage of patients who relapse are cured with a stem cell transplant using the patient’s own cells. However, in patients whose disease becomes resistant to chemotherapy, the average survival is only six months. Until recently, those with B-cell lymphomas that did not respond to standard therapies had limited treatment options.
LGBTQ Health
.program-container {
background-color: #e8f6fb;
padding: 10px;
color: #000000;
}
.program-title {
font: bold 20px Arial,sans-serif;
color: #1B7094;
}
Educational Program Offerings
- Prevention and Early Detection of HPV-Related Cancers for the LGBTQ Community